The Bleeding Risk in Antithrombotic Therapies: A Narrative Review.
Bleeding
acute coronary syndrome
anticoagulants
antiplatelet therapy
atrial fibrillation
clinical predictive rules
percutaneous
coronary intervention
venous thromboembolism.
Journal
Current vascular pharmacology
ISSN: 1875-6212
Titre abrégé: Curr Vasc Pharmacol
Pays: United Arab Emirates
ID NLM: 101157208
Informations de publication
Date de publication:
2020
2020
Historique:
received:
21
06
2018
revised:
02
09
2018
accepted:
28
01
2019
pubmed:
13
2
2019
medline:
21
10
2020
entrez:
13
2
2019
Statut:
ppublish
Résumé
Bleeding represents the most important complication of antithrombotic treatment, including anticoagulant and antiplatelet therapies. A number of scores were proposed to evaluate the risk of bleeding both for anticoagulant and antiplatelet treatment. In the last decade, 5 bleeding risk scores were published for use in atrial fibrillation patients, and 3 scores for patients receiving anticoagulants for venous thromboembolism therapy or prophylaxis. In addition, 3 scores were recently developed to assess inhospital or short-term bleeding risk in patients receiving antiplatelet therapy after Acute Coronary Syndrome (ACS) and Percutaneous Coronary Intervention (PCI). Furthermore, 3 additional scores have focused on long-term bleeding in outpatients receiving dual antiplatelet therapy after PCI. The aim of this review is to consider the evidence on bleeding scores.
Identifiants
pubmed: 30747072
pii: CVP-EPUB-96576
doi: 10.2174/1570161117666190212112743
doi:
Substances chimiques
Anticoagulants
0
Fibrinolytic Agents
0
Platelet Aggregation Inhibitors
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
237-248Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.